Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM -0.35%72 EV-to-OCF is 42.61 as of Aug. 07, 2026, which is 160% above its 10-year median of 16.41. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT19.90 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 448 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 90.63% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Orion Pharma's Enterprise Value is BDT35,017 Mil.
Orion Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was BDT822 Mil. Therefore, Orion Pharma's EV-to-OCF for today is 42.61.
The historical rank and industry rank for Orion Pharma's EV-to-OCF or its related term are showing as below:
DHA:ORIONPHARM'
s EV-to-OCF Range Over the Past 10 Years
Min: 5.94 Med: 16.41 Max: 64.82
Current: 42.67
During the past 12 years, the highest EV-to-OCF of Orion Pharma was 64.82. The lowest was 5.94. And the median was 16.41.
DHA:ORIONPHARM's EV-to-OCF is ranked worse than 90.63% of 448
companies
in the Utilities - Independent Power Producers industry
Industry Median: 9.69
vs DHA:ORIONPHARM: 42.67
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Orion Pharma's PE Ratio (TTM) for today is calculated as:
Orion Pharma's share price for today is BDT28.60.
Orion Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-3.108.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Orion Pharma EV-to-OCF Related Terms
Orion Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Orion Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: EV-to-OCF Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma EV-to-OCF vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Orion Pharma's EV-to-OCF falls into.
Orion Pharma's current Enterprise Value is BDT35,017 Mil.
Orion Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT822 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a EV-to-OCF of 42.61 as of Aug. 07, 2026. This is 160% above median its historical median of 16.41. Over the past decade, Orion Pharma's EV-to-OCF has ranged from 5.94 to 64.82. According to the industry distribution chart, Orion Pharma ranks #406 out of 448 companies in the Utilities - Independent Power Producers industry, placing it in the top 90.6%.
Is Orion Pharma's EV-to-OCF too high?
Orion Pharma's current EV-to-OCF of 42.61 is 160% above median its 10-year median of 16.41. Over the past 10 years, this metric has ranged from a low of 5.94 to a high of 64.82. The Utilities - Independent Power Producers industry median EV-to-OCF is 9.69. Orion Pharma's value of 42.61 is 339.7% above this industry median. Based on the distribution chart, Orion Pharma ranks #406 out of 448 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's EV-to-OCF compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #406 out of 448 companies for EV-to-OCF. This places Orion Pharma in the lower half of its industry. The industry median EV-to-OCF is 9.69. Orion Pharma's value of 42.61 is 339.7% above this benchmark. Historically, Orion Pharma's own EV-to-OCF has ranged from 5.94 to 64.82 over the past decade. While the company's 10-year median is 16.41 vs. the industry median of 9.69, Orion Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for an Utilities - Independent Power Producers company?
The median EV-to-OCF among Utilities - Independent Power Producers companies is 9.69, based on 448 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current EV-to-OCF of 42.61 is 339.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Utilities - Independent Power Producers industry, the median EV-to-OCF is 9.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current EV-to-OCF is 42.61, which is 160% above median its own 10-year median of 16.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT19.90, compared to a current price of BDT28.60 — trading 43.7% above its estimated fair value. The current EV-to-OCF is 42.61, which is 160% above median its 10-year median of 16.41 and 339.7% above the Utilities - Independent Power Producers industry median of 9.69. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current EV-to-OCF is 42.61 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.60 is trading 43.7% above its estimated GF Value™ of BDT19.90.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
EV-to-OCF: 42.61 (160% above median its 10-year median of 16.41)
GF Value™: BDT19.90 vs. price of BDT28.60 (43.7% above fair value)
Industry Position: 339.7% above the Utilities - Independent Power Producers median (#406 of 448)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
